Diametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Diametric Capital LP lessened its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 46.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 354,010 shares of the biopharmaceutical company’s stock after selling 312,829 shares during the period. Diametric Capital LP owned approximately 0.18% of Esperion Therapeutics worth $779,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Intech Investment Management LLC purchased a new position in shares of Esperion Therapeutics in the 3rd quarter worth $94,000. BNP Paribas Financial Markets grew its position in Esperion Therapeutics by 152.7% in the third quarter. BNP Paribas Financial Markets now owns 123,333 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 74,522 shares in the last quarter. MetLife Investment Management LLC increased its stake in Esperion Therapeutics by 47.1% during the third quarter. MetLife Investment Management LLC now owns 71,050 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 22,734 shares during the last quarter. State Street Corp increased its stake in Esperion Therapeutics by 2.7% during the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after acquiring an additional 99,802 shares during the last quarter. Finally, Wellington Management Group LLP raised its position in Esperion Therapeutics by 66.8% during the third quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock valued at $995,000 after purchasing an additional 241,512 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Thursday, March 20th. Finally, Cantor Fitzgerald began coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $6.75.

Esperion Therapeutics Trading Down 4.0 %

Shares of ESPR stock opened at $1.44 on Tuesday. Esperion Therapeutics, Inc. has a twelve month low of $1.42 and a twelve month high of $3.94. The stock has a fifty day simple moving average of $1.76 and a two-hundred day simple moving average of $2.07. The stock has a market capitalization of $284.90 million, a price-to-earnings ratio of -2.25 and a beta of 1.04.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.